CDKN2A and sarcoma: Moreover, the distinctive genotype with activating HER2 mutation, CDKN2A deletion and truncating ATRX mutation, which are identical to those reported in the cited abstract [14], all argue for a distinctive entity unrelated to melanoma, MPNST, or any of the established sarcoma types of the female genital tract or the soft tissues.